Quoin Pharmaceuticals Ltd DRC Asset Resilience Ratio
Quoin Pharmaceuticals Ltd DRC asset resilience ratio. Quoin Pharmaceuticals Ltd DRC (QNRX) has an Asset Resilience Ratio of 58.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Quoin Pharmaceuticals Ltd DRC liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Quoin Pharmaceuticals Ltd DRC (2015–2025)
Asset resilience ratio of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025. This chart shows how Quoin Pharmaceuticals Ltd DRC's Asset Resilience Ratio has changed over time. Read Quoin Pharmaceuticals Ltd DRC total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Quoin Pharmaceuticals Ltd DRC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Quoin Pharmaceuticals Ltd DRC asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.95 Million | 58.1% |
| Total Liquid Assets | $6.95 Million | 58.10% |
Asset Resilience Insights
- Very High Liquidity: Quoin Pharmaceuticals Ltd DRC maintains exceptional liquid asset reserves at 58.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Quoin Pharmaceuticals Ltd DRC Industry Peers by Asset Resilience Ratio
Compare Quoin Pharmaceuticals Ltd DRC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Quoin Pharmaceuticals Ltd DRC Asset Resilience Ratio by Year (2015–2025)
Quoin Pharmaceuticals Ltd DRC asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Quoin Pharmaceuticals Ltd DRC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.21% | $14.93 Million | $20.39 Million | +6.79pp |
| 2024-12-31 | 66.42% | $10.43 Million | $15.71 Million | -1.74pp |
| 2023-12-31 | 68.15% | $8.29 Million | $12.17 Million | -0.96pp |
| 2022-12-31 | 69.12% | $9.99 Million | $14.46 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $9.36 Million | -- |
| 2017-12-31 | 46.09% | $4.03 Million | $8.75 Million | -26.62pp |
| 2016-12-31 | 72.71% | $6.41 Million | $8.81 Million | +14.12pp |
| 2015-12-31 | 58.60% | $2.01 Million | $3.43 Million | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more